Stockreport

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression [Ya...

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF Initial results from the recently completed monotherapy Part 1 of the study were shared in March 2024 and showed that a single dose of BPL-003 was safe and well-tolerat [Read more]